Stay tuned
Seagen, after $42M victory, suffers loss in ADC patent feud with Daiichi
Seagen, after $42M victory, suffers loss in ADC patent feud with Daii
Two deaths after Novartis' Zolgensma put gene therapy’s liver safety in the spotlight once again
Two deaths after Novartis' Zolgensma put gene therapy’s liver safet
Pfizer in catch-up mode with Merck shows data that could fetch Prevnar 20 a key approval
Pfizer in catch-up mode with Merck shows data that could fetch Prevna
AZ, Daiichi Sankyo's Enhertu breaks more ground, nabbing fast FDA nod in HER2-mutant lung cancer
AZ, Daiichi Sankyo's Enhertu breaks more ground, nabbing fast FDA nod
After billions in legal costs, Johnson & Johnson plans to halt talc sales worldwide
After billions in legal costs, Johnson & Johnson plans to halt ta
Stay tuned
© 1994 - 2022 B.M. Pharmaceuticals